Abstract
Fatty acid-binding protein (FABP) 4 is an adipocytokine mainly expressed in adipocyte and macrophage. Blood FABP4 is related not only to metabolic disorders including insulin resistance and atherosclerosis but also increased blood pressure. We tested the hypothesis that FABP4 plays roles in pathogenesis of hypertension development including proliferation, migration, and inflammation of vascular smooth muscle cells (SMCs) as well as contractile reactivity. FABP4 alone had no influence on proliferation, migration, and inflammation of rat mesenteric arterial SMCs, while it significantly enhanced smooth muscle contraction and increases of systolic blood pressure (SBP) induced by noradrenaline (NA). BMS-309403, an FABP4 inhibitor, significantly inhibited platelet-derived growth factor-BB-induced DNA synthesis and migration via preventing p38 and HSP27 activation. Further, BMS-309403 significantly inhibited tumor necrosis factor-α-induced expression of vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 as well as monocyte adhesion via preventing NF-κB activation. Interestingly, SMCs do not express FABP4. Long-term treatment of spontaneously hypertensive rats (SHR) with BMS-309403 significantly inhibited impaired relaxation in isolated mesenteric arteries and left ventricular hypertrophy, while it had no influence on SBP. We for the first time showed that FABP4 acutely enhances NA-induced increases of SBP possibly through the enhancement of peripheral arterial contractility. BMS-309403 prevents proliferation, migration, and inflammatory responses of SMCs, although exogenous application of FABP4 has no influence on the cellular responses. Furthermore, we demonstrated that long-term treatment with BMS-309403 partially improves the pathological conditions of SHR. These results indicate that BMS-309403 would be useful for developing a new pharmacotherapeutic agent against obesity-associated hypertension and complications.
Similar content being viewed by others
References
Aragones G, Saavedra P, Heras M, Cabre A, Girona J, Masana L (2012) Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol 11:72. doi:10.1186/1475-2840-11-72
Astern JM, Pendergraft WF 3rd, Falk RJ, Jennette JC, Schmaier AH, Mahdi F, Preston GA (2007) Myeloperoxidase interacts with endothelial cell-surface cytokeratin 1 and modulates bradykinin production by the plasma Kallikrein-Kinin system. Am J Pathol 171:349–360. doi:10.2353/ajpath.2007.060831
Azzazy HM, Pelsers MM, Christenson RH (2006) Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem 52:19–29. doi:10.1373/clinchem.2005.056143
Bhushan B, Khalyfa A, Spruyt K, Kheirandish-Gozal L, Capdevila OS, Bhattacharjee R, Kim J, Keating B, Hakonarson H, Gozal D (2011) Fatty-acid binding protein 4 gene polymorphisms and plasma levels in children with obstructive sleep apnea. Sleep Med 12:666–671. doi:10.1016/j.sleep.2010.12.014
Boss M, Kemmerer M, Brune B, Namgaladze D (2015) FABP4 inhibition suppresses PPARgamma activity and VLDL-induced foam cell formation in IL-4-polarized human macrophages. Atherosclerosis 240:424–430. doi:10.1016/j.atherosclerosis.2015.03.042
Cabre A, Lazaro I, Cofan M, Jarauta E, Plana N, Garcia-Otin AL, Ascaso JF, Ferre R, Civeira F, Ros E, Masana L (2010) FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res 51:1173–1178. doi:10.1194/jlr.M900066
Chan CK, Zhao Y, Liao SY, Zhang YL, Lee MY, Xu A, Tse HF, Vanhoutte PM (2013) A-FABP and oxidative stress underlie the impairment of endothelium-dependent relaxations to serotonin and the intima-medial thickening in the porcine coronary artery with regenerated endothelium. ACS Chem Neurosci 4:122–129. doi:10.1021/cn3000873
Choi OB, Park JH, Lee YJ, Lee CK, Won KJ, Kim J, Lee HM, Kim B (2009) Olibanum extract inhibits vascular smooth muscle cell migration and proliferation in response to platelet-derived growth factor. Korean J Physiol Pharmacol 13:107–113. doi:10.4196/kjpp.2009.13.2.107
Distel RJ, Robinson GS, Spiegelman BM (1992) Fatty acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms. J Biol Chem 267:5937–5941
Furuhashi M, Tuncman G, Gorgun CZ, Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S, Linton MF, Sulsky R, Robl JA, Parker RA, Hotamisligil GS (2007) Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447:959–965. doi:10.1038/nature05844
Gan J, Li P, Wang Z, Chen J, Liang X, Liu M, Xie W, Yin R, Huang F (2013) Rosuvastatin suppresses platelet-derived growth factor-BB-induced vascular smooth muscle cell proliferation and migration via the MAPK signaling pathway. Exp Ther Med 6:899–903. doi:10.3892/etm.2013.1265
Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M (2014) FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with PPARgamma in adipose tissues. Diabetes 63:900–911. doi:10.2337/db13-0436
Girona J, Rosales R, Plana N, Saavedra P, Masana L, Vallve JC (2013) FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One 8:e81914. doi:10.1371/journal.pone.0081914
Hasan AA, Zisman T, Schmaier AH (1998) Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sci U S A 95:3615–3620
Hertzel AV, Bernlohr DA (2000) The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 11:175–180
Hertzel AV, Hellberg K, Reynolds JM, Kruse AC, Juhlmann BE, Smith AJ, Sanders MA, Ohlendorf DH, Suttles J, Bernlohr DA (2009) Identification and characterization of a small molecule inhibitor of fatty acid binding proteins. J Med Chem 52:6024–6031. doi:10.1021/jm900720m
Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM (1996) Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274:1377–1379
Hunt CR, Ro JH, Dobson DE, Min HY, Spiegelman BM (1986) Adipocyte P2 gene: developmental expression and homology of 5′-flanking sequences among fat cell-specific genes. Proc Natl Acad Sci U S A 83:3786–3790
Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Omata M, Kimura K (2006) Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 284:175–182. doi:10.1007/s11010-005-9047-9
Kazama K, Usui T, Okada M, Hara Y, Yamawaki H (2012) Omentin plays an anti-inflammatory role through inhibition of TNF-alpha-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 686:116–123. doi:10.1016/j.ejphar.2012.04.033
Kazama K, Okada M, Hara Y, Yamawaki H (2013) A novel adipocytokine, omentin, inhibits agonists-induced increases of blood pressure in rats. J Vet Med Sci 75:1029–1034
Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ (1992) Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 116:155–162
Kubo T (1998) Cholinergic mechanism and blood pressure regulation in the central nervous system. Brain Res Bull 46: 475–481. doi:10.1016/S0361-9230(98)00041-0
Kunimoto H, Kazama K, Takai M, Oda M, Okada M, Yamawaki H (2015) Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure. Am J Physiol Heart Circ Physiol 309:H1017–H1028. doi:10.1152/ajpheart.00820.2014
Lee MY, Li H, Xiao Y, Zhou Z, Xu A, Vanhoutte PM (2011) Chronic administration of BMS309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells. Br J Pharmacol 162:1564–1576. doi:10.1111/j.1476-5381.2010.01158.x
Machida THT, Onoguchi A, Iizuka K, Hirafuji M (2014) Comparison of fatty acid-binding protein expression in vascular smooth muscle cells from stroke-prone spontaneously hypertensive and Wistar Kyoto rats. Pharmacologia 5:12–18. doi:10.5567/pharmacologia.2014.12.18
Maeda K, Cao H, Kono K, Gorgun CZ, Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, Minokoshi Y, Kahn BB, Parker RA, Hotamisligil GS (2005) Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1:107–119. doi:10.1016/j.cmet.2004.12.008
Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF (2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699–705. doi:10.1038/89076
Melki SA, Abumrad NA (1993) Expression of the adipocyte fatty acid-binding protein in streptozotocin-diabetes: effects of insulin deficiency and supplementation. J Lipid Res 34:1527–1534
Morita T, Okada M, Hara Y, Yamawaki H (2011) Mechanisms underlying impairment of endothelium-dependent relaxation by fetal bovine serum in organ-cultured rat mesenteric artery. Eur J Pharmacol 668:401–406. doi:10.1016/j.ejphar.2011.07.040
Ockner RK, Manning JA, Poppenhausen RB, Ho WK (1972) A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science 177:56–58
Ota H, Furuhashi M, Ishimura S, Koyama M, Okazaki Y, Mita T, Fuseya T, Yamashita T, Tanaka M, Yoshida H, Shimamoto K, Miura T (2012) Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 25:1124–1130. doi:10.1038/ajh.2012.88
Otani K, Okada M, Yamawaki H (2015) Expression pattern and function of tyrosine receptor kinase B isoforms in rat mesenteric arterial smooth muscle cells. Biochem Biophys Res Commun 467:683–689. doi:10.1016/j.bbrc.2015.10.084
Phalitakul S, Okada M, Hara Y, Yamawaki H (2012) A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun 423:844–849. doi:10.1016/j.bbrc.2012.06.052
Pichon S, Bryckaert M, Berrou E (2004) Control of actin dynamics by p38 MAP kinase—Hsp27 distribution in the lamellipodium of smooth muscle cells. J Cell Sci 117:2569–2577. doi:10.1242/jcs.01110
Saavedra P, Girona J, Bosquet A, Guaita S, Canela N, Aragones G, Heras M, Masana L (2015) New insights into circulating FABP4: interaction with cytokeratin 1 on endothelial cell membranes. Biochim Biophys Acta 1853:2966–2974. doi:10.1016/j.bbamcr.2015.09.002
Sulsky R, Magnin DR, Huang Y, Simpkins L, Taunk P, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R, Harrity T, Stoffel R, Taylor DS, Lavoie TB, Kish K, Jacobson BL, Sheriff S, Adam LP, Ewing WR, Robl JA (2007) Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP). Bioorg Med Chem Lett 17:3511–3515. doi:10.1016/j.bmcl.2006.12.044
Terra X, Quintero Y, Auguet T, Porras JA, Hernandez M, Sabench F, Aguilar C, Luna AM, Del Castillo D, Richart C (2011) FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women. Eur J Endocrinol 164:539–547. doi:10.1530/EJE-10-1195
Usui T, Okada M, Hara Y, Yamawaki H (2012) Death-associated protein kinase 3 mediates vascular inflammation and development of hypertension in spontaneously hypertensive rats. Hypertension 60:1031–1039. doi:10.1161/HYPERTENSIONAHA.112.200337
Usui T, Morita T, Okada M, Yamawaki H (2014) Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells. Hypertension 63:397–403. doi:10.1161/HYPERTENSIONAHA.113.01843
Uysal KT, Scheja L, Wiesbrock SM, Bonner-Weir S, Hotamisligil GS (2000) Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 141:3388–3396. doi:10.1210/endo.141.9.7637
Acknowledgements
This study was supported by Grants for Scientific Research from Japan Society for the Promotion of Science and School of Veterinary Medicine, The Kitasato University.
Author information
Authors and Affiliations
Corresponding author
Additional information
Yuta Okamura and Kosuke Otani are co-first authors.
Topical Collection on Signaling and cell physiology
Electronic supplementary material
ESM 1
(PDF 124 kb)
Rights and permissions
About this article
Cite this article
Okamura, Y., Otani, K., Sekiguchi, A. et al. Vasculo-protective effect of BMS-309403 is independent of its specific inhibition of fatty acid-binding protein 4. Pflugers Arch - Eur J Physiol 469, 1177–1188 (2017). https://doi.org/10.1007/s00424-017-1976-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00424-017-1976-0